Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases.

Intercept

GENFIT is a biopharmaceutical company focused on the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases.

GENFIT

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Zydus

Humanetics Corporation is a clinical-stage pharmaceutical company focused on developing and commercializing proprietary drugs for the treatment of chronic diseases.

Humanetics

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel drugs for the treatment of various diseases.

Arena Pharmaceuticals

Intarcia Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for chronic diseases, with a focus on diabetes and other metabolic conditions.

Intarcia Therapeutics

Otitopic is a biopharmaceutical company focused on developing therapies for ear-related disorders and diseases.

Otitopic

Trifecta Clinical is a clinical research organization (CRO) that provides comprehensive services for the development and execution of clinical trials in various therapeutic areas.

Trifecta Clinical

DURECT Corporation is a biopharmaceutical company focused on the development of innovative therapies for the treatment of chronic and acute diseases, with a focus on pain management.

DURECT Corporation

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies to treat liver and other chronic diseases. Its lead product candidate, seladelpar (MBX-8025), is a selective agonist of peroxisome proliferator-activated receptor delta for the treatment of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics.

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

Silicon Valley Bank

Oxford Finance LLC

Abingworth

Venrock

Versant Ventures

Birchmere Ventures

Merlin Biomed

Next Chapter Holdings

Alta Partners

Bay City Capital

CymaBay Therapeutics

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

NASDAQ:CBAY

CymaBay Therapeutics Inc

Last Close

32.47

21/03 20:00

Market Cap

2.61B

Beta: 0.26

Volume Today

8.35M

Avg: 1.67M

PE Ratio

−23.78

PFCF: −42.19